“Success is walking from failure to failure with no loss of enthusiasm.”

— Winston Churchill

Intellia Therapeutics – N T L A  https://www.intelliatx.com/pipeline-2/

  • Current Market Capitalization:  $757M
  • 52 weeks high $32.95;  52 weeks low $15.34
  • Target on $1.4B  for acquisition premium; technical breakout to $22

Upcoming catalyst:  

  • IND filing for ATTR  between Q4 to Q1 of 2020
  • possibility of collaboration with Novartis expands cell therapy which is set to expire in December 2019
  • lastly, the recent M&A for the sector was focused on Gene therapy, the Giants Pharmaceuticals have acquired  4 in this year alone.

Recent Gene therapy acquisitions-

  •  3/25/19  Brammer Bio $1.7B by Thermo Fischer;  Thermo Fisher
  • 3/20/2019  Vivet Therapeutics by Pfizer- upfront $51M of 15% interest & up to $635.8M or 100% of  Vivet Ph1/2 clinical trial for VTX-801
  • 3/4/ 2019 NITE $800M by Biogen;
  • 2/22/19  ONCE $4.8B by Roche – expected completion on June 3, 2019;